Ultra Market Research | Autologous Cell Therapy Market
Comprehensive Analysis of the Autologous Cell Therapy Market Trends and Growth Opportunities

Autologous Cell Therapy Market

  • Report ID : 586

  • Category : Pharmaceuticals

  • No Of Pages : 150

  • Published on: July 2024

  • Status: Published

  • Format : Power Point PDF Excel Word

Key Question Answer

check-box

Global Market Outlook

check-box

In-depth analysis of global and regional trends

check-box

Analyze and identify the major players in the market, their market share, key developments, etc.

check-box

To understand the capability of the major players based on products offered, financials, and strategies.

check-box

Identify disrupting products, companies, and trends.

check-box

To identify opportunities in the market.

check-box

Analyze the regional penetration of players, products, and services in the market.

check-box

Comparison of major players financial performance.

check-box

Evaluate strategies adopted by major players.

check-box

Recommendations


Autologous Cell Therapy Market


Market for autologous cell therapy was estimated to be worth US$ XX billion globally in 2023 and is projected to reach US$ XX billion by 2033, expanding at a compound annual growth rate (CAGR) of XX% between 2024 and 2033. The groundbreaking development of autologous therapy has reignited interest in cell therapy projects. This novel method replaces damaged bone marrow after chemotherapy, radiation therapy, or other cancer therapies by using healthy cells from the patient's peripheral blood. Significant major factors propelling the autologous cell treatment market's rise are its efficacy and promise in treating serious health disorders.


Market Overview
Driven by the novel process of obtaining and preserving a patient's healthy stem cells from blood or bone marrow prior to treatment, then reintroducing them thereafter, the autologous cell therapy business is expanding quickly. Treating blood malignancies like lymphoma and leukaemia is especially successful with this method because it replaces stem cells that have been damaged by radiation or intense chemotherapy. Autologous cell treatment greatly lowers the chance of donor-patient incompatibility by using the patient's own cells. This treatment, which includes taking cells straight from the patient and using leukapheresis to target them, is only available to patients who have sufficient cell supply for apheresis. Research into B cells, NK cells, and dendritic cells for therapy is growing in addition to T cells. Specifically, autologous CAR T-cell therapy targets and and selects healthy T cells from the patient’s peripheral blood, highlighting the market's potential and continued expansion.
•    In February 2024, BioNTech and Autolus announced a strategic CAR-T cell therapy collaboration to advance their pipeline and expand late-stage programs. 
Source: https://autolus.gcs-web.com/news-releases/news-release-details/biontech-and-autolus-announce-strategic-car-t-cell-therapy

 

Key Insights

•    North America generated largest market share.
•    Asia Pacific is predicted to grow at the fastest CAGR in forecast period.
•    By Source, the bone marrow segment is expected to record the maximum market share.
•    By Application, the cancer segment has held a largest market share.
•    By Application, the cardiovascular segment is expected to expand at a remarkable CAGR in forecast period.
•    By End-use, the hospitals & clinics segment is projected to capture the biggest revenue share


Regional Stance
During the projection period, North America is anticipated to dominate the autologous cell therapy market, with Canada developing as a potent centre for CAR-T manufacture. Canada maintains a strong commitment to regulatory compliance and provides clients with complete capabilities in automation, closed system bioreactors, upstream and downstream processing. Canada is at the forefront of the global cellular treatment scene thanks to its collaborative attitude and commitment to sustainability. The country offers dependable and creative support for the development and manufacturing of cutting-edge CAR-T therapies. The main association for scientists, doctors, patient advocates, and other gene and cell therapy professionals is the American Society of Gene & Cell Therapy (ASGCT). In Mexico, stem cell therapy combines platelet-rich plasma therapy with allogeneic mesenchymal stem cells that are acquired using a unique cryopreservation method that guarantees over 97% viability at transplantation to get the best possible working qualities.
•    In February 2024, AstraZeneca expanded its US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development. 

Over the course of the projection period, the Asia Pacific region is expected to develop at the fastest CAGR, with China emerging as a key participant in CAR-T technology. Patients from around the world seeking CAR-T cell therapy for diseases including multiple myeloma and lymphoma find China to be a desirable destination due to its abundance of clinical trials and affordable treatment expenses. CAR-T therapy is available at several hospitals around China, with differing degrees of medical care and customer support. When the Central Drugs Standard Control Organisation, India's equivalent of the US FDA, approved NexCAR19 in October 2023, it was a historic moment as it was the country's first CAR-T cell therapy to be licensed.
•    In April 2024, the President of India launched India’s first home-grown gene therapy for cancer, developed by IIT Bombay, Tata Memorial Centre, and ImmunoACT. 
 

Report Highlights     
By Source
Source states that bone marrow, mesenchymal stem cells, haematopoietic stem cells, chondrocytes, epidermis, and others are the different segments of the global autologous cell treatment market. Over the course of the forecast period, the bone marrow category is anticipated to earn the biggest revenue share. The soft, porous tissue called bone marrow found in the centre of bones is essential for the production of healthy red blood cells. The reintroduction of harvested stem cells into the bloodstream during autologous cell treatment allows the bone marrow to produce new blood cells, which is what propels the bone marrow segment's market domination.
Over the course of the forecast period, the Mesenchymal Stem Cells (MSCs) sector is expected to increase at the fastest rate. Stem cells, or MSCs, are able to differentiate into multiple lineages and self-renew. Menstrual blood, bone marrow, adipose tissue, endometrial polyps, and the umbilical cord are just a few of the tissues from which they can be separated. The MSCs section of the autologous cell treatment market is rapidly expanding due to the practical advantages of being easy to harvest and having considerable quantity. These sources are particularly ideal for both experimental and possible clinical applications.
 

By Application
Market is divided into categories based on application, including orthopaedics, wound healing, neurodegenerative disorders, autoimmune disorders, cancer, and others. It is projected that during the course of the projection period, the cancer sector would lead the market. Autologous stem cell transplants are mostly utilised for the treatment of blood malignancies, including lymphoma and leukaemia. Blood is extracted from a vein, processed through an apheresis machine to remove stem cells, and the remaining blood is then given back to the patient are the basic phases in the procedure. After that, the patient receives chemotherapy, which kills healthy cells that create blood vessels in addition to targeting cancer cells. This process emphasises how important autologous stem cell transplants are for the treatment of cancer, which fuels the market leadership of the segment.
Source: https://escovaccixcell.com/applications/cell-therapy/autologous-cell-therapy 
Over the course of the forecast period, the cardiovascular segment is expected to see significant increase. Autologous cell therapy is a quickly developing therapeutic approach with implications in immuno-oncology and regenerative medicine. This cutting-edge method is being used more often to treat a variety of cardiovascular diseases (CVDs), addressing the common characteristics and problems unique to each stage of these illnesses. This market is predicted to increase significantly as long as cell therapy is developed and used in cardiovascular care.
 

By End User
Market is divided into four segments based on end-use: Academics & Research, Hospitals & Clinics, Ambulatory Centres, and Others. Over the course of the projection period, the Hospitals & Clinics category is anticipated to earn the greatest revenue share. Cells from a patient's biopsy are used to create autologous, or patient-specific, cell therapies. The cells are then processed to meet the needs of the therapy and are reintroduced into the patient through infusion or surgery. This method, which uses a patient's own stem cells to treat a range of illnesses, is primarily carried out in clinics and hospitals. Mesenchymal and haematopoietic stem cells are the two adult stem cell types most frequently used in this therapy, highlighting the vital role that hospitals and clinics play in the administration and management of autologous stem cell treatments.
Over the course of the projection period, a significant growth is expected in the Academics & Research segment. This section is essential to the advancement of autologous stem cell transplantation, a process that uses a patient's own stem cells for transplantation. Before the patient receives large dosages of chemotherapy, either with or without radiation therapy, stem cells are extracted and stored. The patient receives a reintroduction of the frozen stem cells into their body after treatment. The continuous investigations and scholarly pursuits in this field are essential for optimising methods, enhancing results, and broadening the scope of autologous stem cell therapy.

Market Dynamics
Driver 
Broad Applications in Dermatology
Autologous therapy is a revolutionary therapeutic intervention with broad implications in orthopaedics, therapeutic and cosmetic dermatology, and modern medicine. It involves using a donor's cells or tissues that have been treated outside of their body and then reintroduced into the donor. Because it overcomes some of the challenges associated with standard therapies, this type of therapy has great potential in the field of dermatology. Key factors propelling the growth of the autologous cell therapy market include the increasing application and efficacy of autologous therapies across a range of medical specialities.

Restraints
High Costs and Severe Side Effects 
Delays in the autologous therapy process can be catastrophic for patients who are near death. The procedure can take up to one month. The elevated expense, which can range from $370,000 to $475,000 for each treatment, presents a notable obstacle to accessibility. If severe side effects like cytokine release syndrome (CRS), which occurs when reintroduced cells cause an overwhelming immune response, are not swiftly handled, the results might be disastrous, including substantial organ failure and death. These elements severely limit the market's ability to expand for autologous cell treatment.
 

Opportunities
Automation and AI Integration 
Hospitals may now independently produce autologous CAR-T cell products, greatly improving production robustness and cost-effectiveness, thanks to the astute integration of automated CAR-T cell manufacturing systems. Making judgements on process optimisation is facilitated by using artificial intelligence (AI) to analyse data gathered on these platforms. This approach yields insightful findings. To treat large numbers of patients at the cutting edge of autologous CAR-T cell treatments, a revolutionary automated manufacturing strategy is necessary. Parallelised production should be possible with such a system in order to lower costs and improve product availability. Because of its integrated yet modular design, it can swiftly adjust to technological developments in ATMP manufacturing while requiring less manual interventions, which presents the autologous cell therapy market with tremendous potential opportunities.

•    In May 2024, Cytiva rolled out a new CAR-T manufacturing platform developed in collaboration with Gilead's Kite. 
Source: https://www.fiercepharma.com/manufacturing/cytiva-rolls-out-new-car-t-manufacturing-platform-developed-gileads-kite


Recent Developments

•    In March 2024, the NMPA approved the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for relapsed or refractory multiple myeloma. 
•    In August 2023, Precision BioSciences completed a strategic transaction with Imugene for Azer-Cel in cancer. Source: 
•    In February 2024, BioNTech and Autolus announced a strategic CAR-T cell therapy collaboration to advance their pipeline and expand late-stage programs. 
 

Key Players in the Autologous Cell Therapy Market
Autolus Therapeutics
Lineage Cell Therapeutics, Inc.
Sangamo Therapeutics
Holostem Terapie Avanzate S.r.l.
Vericel Corporation
Opexa Therapeutics
BrainStorm Cell Therapeutics
Pharmicell Co., Inc.
Bayer AG
Daiichi Sankyo Co., Ltd
Takeda Pharmaceutical Co., Ltd
Sumitomo Chemical Co., Ltd


Market Segmentation
By Source
Epidermis
Bone Marrow
Mesenchymal Stem Cells
Haematopoietic Stem Cells
Chondrocytes
Others
By Application
Cancer
Cardiovascular Disorders
Neurodegenerative Disorders
Autoimmune Disorders
Orthopedics
Wound Healing
Others
By End-Use
Hospitals & Clinics
Ambulatory Centers
Academics & Research
Others



By Geography
North America
U.S.
Canada
Europe
Germany
France
United Kingdom
Rest of Europe
 Asia Pacific
 China
Japan
India
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
Middle East & Africa (MEA)
GCC
North Africa
South Africa
  Rest of Middle East & Africa

 

Choose License Type

  • $3999

  • $5550

  • $6999

Our Reports Look Like This

Ultra Market Research

HAVE A QUESTION

will help you find what you are looking for:


Related Reports

Recent Reports

Subscribe to Newsletter

Provide your email to get email notification when we publish new reports.

whatsapp